Where to buy Binimetinib

Binimetinib is approved along with encorafenib to treat patients with cancers that have specific mutations in the BRAF gene, including melanoma that cannot be removed with surgery or has spread to other parts of the body, or non-small cell lung cancer, which occurs in adults whose cancer has spread to other parts of the body. Bimetinib is also being studied to treat other types of cancer.

Bimetinib, trade nameMektovi, is an anticancer drug used to treat various cancers. Developed byArray Biopharma, bimetinib is an oral mitogen-activated protein kinase kinase (MEK) inhibitor, more specifically, a MAP2K inhibitor. MEK is part of the RAS pathway and is involved in cell proliferation and survival. MEK is upregulated in a variety of cancers. Bimetinib, which does not compete with ATP, binds to and inhibits the activity of MEK1/2 kinase, which has been shown to regulate several key cellular activities, including proliferation, survival and angiogenesis. As shown in preclinical studies, this may ultimately lead to inhibition of tumor cell proliferation and suppression of the production of various inflammatory cytokines, including interleukin-1, -6 and tumor necrosis factor.

The original drug Bimetinib has not yet been launched in China, so it is not included in the scope of medical insurance. Patients in need cannot purchase this drug through domestic hospitals and other places. Bimetiniboriginal drug sold overseas, specifications15mg*84 tablets may cost more than 10,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic drug of Bimetinib produced and launched. For more drug information and specific prices, please consult a medical consultant.